Patients will take metformin twice a day for three weeks prior surgery

Drug: Metformin Pre-Surgery

500 mg tablet, taken twice a day for 3 weeks

Other Names:

Laboratory biomarker analysis

Blood and tissue collection

Detailed Description:

Patients will take metformin twice a day for 3 weeks before surgery. The hypothesis is that metformin will reduce cell proliferation rates (Ki67) and increase apoptoses (TUNEL)in tumor tissue.

The study will collect and analyze pre- and post-treatment blood specimens for:

Serum glucose

Insulin levels

Estradiol

HOMA test

Glycosylated haemoglobin

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Female

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Invasive breast cancer T1 or T2, Nx

Knowledge of the investigational nature of the study and ability to provide consent for study participation

Exclusion Criteria:

Diabetes or baseline glucose or Glycosylated haemoglobin upper limit of normal for the institution

Recent use of corticosteroids

AST > 1.5 times upper limit of normal for the institution

Pregnancy

Serious clinical illness

Prior or concurrent systemic neoadjuvant Breast Cancer therapy.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01302002